tradingkey.logo

Femasys Inc

FEMY
View Detailed Chart

0.350USD

-0.010-2.72%
Close 09/19, 16:00ETQuotes delayed by 15 min
11.40MMarket Cap
LossP/E TTM

Femasys Inc

0.350

-0.010-2.72%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.72%

5 Days

-10.74%

1 Month

-47.82%

6 Months

-77.71%

Year to Date

-68.18%

1 Year

-70.09%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
118 / 207
Overall Ranking
273 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
6.250
Target Price
+1637.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.14.
Overvalued
The company’s latest PE is -0.41, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.74M shares, increasing 6.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 951.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.15.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Ticker SymbolFEMY
CompanyFemasys Inc
CEOMs. Kathy Lee-Sepsick
Websitehttps://www.femasys.com/
KeyAI